Patents by Inventor Bud C. Tennant

Bud C. Tennant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating hepatitis delta virus infection
    Patent number: 7511027
    Abstract: A method for the treatment for hepatitis delta infection in a host, that includes administering an effective amount of a nucleoside or a nucleoside analog that suppresses the expression of the hepatitis B surface or preS1 antigen in the host 100-fold or more relative to pretreatment values in vivo; or to not more than 1 microgram per milliliter in vivo. In a preferred embodiment, the nucleoside is L-FMAU, or a pharmaceutically acceptable salt or prodrug thereof.
    Type: Grant
    Filed: November 22, 2002
    Date of Patent: March 31, 2009
    Assignees: Georgetown University, University of Georgia Research Foundation, Inc.
    Inventors: John L. Casey, Brent E. Korba, Paul J. Cote, John L. Gerin, Bud C. Tennant, Chung K. Chu
  • Animal model for flaviviridae infection
    Patent number: 6878364
    Abstract: The present invention is a woodchuck or an isolated woodchuck cell infected with bovine viral diarrhea virus. The invention can be used to identify new compounds for the treatment of flavivirus, pestivirus or hepatitis C infection using these models.
    Type: Grant
    Filed: December 3, 2001
    Date of Patent: April 12, 2005
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Edward J. Dubovi, Bud C. Tennant, James R. Jacob
  • Method of treating hepatitis delta virus infection
    Patent number: 6670342
    Abstract: A method for the treatment for hepatitis delta infection in a host, that includes administering an effective amount of a nucleoside or a nucleoside analog that suppresses the expression of the hepatitis B surface or preS1 antigen in the host 100-fold or more relative to pretreatment values in vivo; or to not more than 1 microgram per milliliter in vivo. In a preferred embodiment, the nucleoside is L-FMAU, or a pharmaceutically acceptable salt or prodrug thereof.
    Type: Grant
    Filed: March 29, 2001
    Date of Patent: December 30, 2003
    Assignees: Georgetown University, Cornell Research Foundation, Inc., University of Georgia Research Foundation, Inc.
    Inventors: John L. Casey, Brent E. Korba, Paul J. Cote, John L. Gerin, Bud C. Tennant, Chung K. Chu
  • Method of treating hepatitis delta virus infection
    Publication number: 20030158149
    Abstract: A method for the treatment for hepatitis delta infection in a host, that includes administering an effective amount of a nucleoside or a nucleoside analog that suppresses the expression of the hepatitis B surface or preS1 antigen in the host 100-fold or more relative to pretreatment values in vivo; or to not more than 1 microgram per milliliter in vivo. In a preferred embodiment, the nucleoside is L-FMAU, or a pharmaceutically acceptable salt or prodrug thereof.
    Type: Application
    Filed: November 22, 2002
    Publication date: August 21, 2003
    Inventors: John L. Casey, Brent E. Korba, Paul J. Cote, John L. Gerin, Bud C. Tennant, Chung K. Chu
  • Animal model for flaviviridae infection
    Publication number: 20030037353
    Abstract: The present invention is a woodchuck or an isolated woodchuck cell infected with bovine viral diarrhea virus. The invention can be used to identify new compounds for the treatment of flavivirus, pestivirus or hepatitis C infection using these models.
    Type: Application
    Filed: December 3, 2001
    Publication date: February 20, 2003
    Inventors: Edward J. Dubovi, Bud C. Tennant, James R. Jacob
  • Method of treating hepatitis delta virus infection
    Publication number: 20020160980
    Abstract: A method for the treatment for hepatitis delta infection in a host, that includes administering an effective amount of a nucleoside or a nucleoside analog that suppresses the expression of the hepatitis B surface or preS1 antigen in the host 100-fold or more relative to pretreatment values in vivo; or to not more than 1 microgram per milliliter in vivo. In a preferred embodiment, the nucleoside is L-FMAU, or a pharmaceutically acceptable salt or prodrug thereof.
    Type: Application
    Filed: March 29, 2001
    Publication date: October 31, 2002
    Inventors: John L. Casey, Brent E. Korba, Paul J. Cote, John L. Gerin, Bud C. Tennant, Chung K. Chu